A Plus Biotechnology Co., Ltd. (TPE:6918)
Taiwan · Delayed Price · Currency is TWD 73.00
-0.10 (-0.14%)
At close: May 28, 2026
A Plus Biotechnology Revenue
A Plus Biotechnology had revenue of 219.39M TWD in the quarter ending March 31, 2026, with 11.71% growth. This brings the company's revenue in the last twelve months to 858.89M, up 8.99% year-over-year. In the year 2025, A Plus Biotechnology had annual revenue of 835.89M with 8.61% growth.
Revenue (ttm)
858.89M
Revenue Growth
+8.99%
P/S Ratio
2.88
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 835.89M | 66.30M | 8.61% |
| Dec 31, 2024 | 769.59M | 94.54M | 14.01% |
| Dec 31, 2023 | 675.05M | 133.20M | 24.58% |
| Dec 31, 2021 | 541.85M | 38.56M | 7.66% |
| Dec 31, 2020 | 503.29M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Wellell | 2.43B |
| OK Biotech | 1.53B |
| Dynamic Medical Technologies | 1.38B |
| WeLeader Biomedical | 1.14B |
| Bioptik Technology Incorporation | 865.76M |
| Medimaging Integrated Solution | 675.15M |
| Applied BioCode | 572.33M |
| Diamond Biotechnology | 501.49M |